– Pharma R&D sees lower success amid the crisis

LONDON–(BUSINESS WIRE)–#Analytics—Quantzig, global data analytics and advisory firm, that delivers actionable analytics solutions to resolve complex business problems has been actively analyzing the current pharma landscape and the impact of the ongoing crisis on pharmaceutical R&D.

Based on its analysis, it is clear that pharmaceutical R&D suffers from decreasing success rates and a stagnant pipeline due to several interconnected factors.

Quantzig’s real world evidence analytics experts, said. “Today, stakeholders across the entire healthcare value chain including physicians, providers, payors, regulatory bodies, and pharmaceutical and medical device manufacturers are using real world evidence analytics to guide their decisions.”